Three-Dimensional Quantitative Structure-Activity Relationships of Inhibitors of P-Glycoprotein

Molecular Pharmacology
2002.0

Abstract

P-glycoprotein (P-gp) is an efflux transporter involved in limiting the oral bioavailability and tissue penetration of a variety of structurally divergent molecules. A better understanding of the structural requirements of modulators of P-gp function will aid in the design of therapeutic agents. Toward this goal, three-dimensional quantitative structure-activity relationship (3D-QSAR) models were generated using in vitro data associated with inhibition of P-gp function. Several approaches were undertaken with multiple iterations, yielding Catalyst 3D-QSAR models being able to qualitatively rank-order and predict IC(50) values for P-gp inhibitors excluded from the model in question. The success of these validations suggests that a P-gp pharmacophore for 27 inhibitors of digoxin transport in Caco-2 cells consisted of four hydrophobes and one hydrogen bond acceptor. A second pharmacophore generated with 21 inhibitors of vinblastine binding to plasma membrane vesicles derived from CEM/VLB(100) cells contained three ring aromatic features and one hydrophobic feature. A third pharmacophore generated with 17 inhibitors of vinblastine accumulation in P-gp expressing LLC-PK1 cells contained four hydrophobes and one hydrogen bond acceptor. A final pharmacophore was generated for inhibition of calcein accumulation in P-gp expressing LLC-PK1 cells and found to contain two hydrophobes, a ring aromatic feature, and a hydrogen bond donor. The similarity of features for the pharmacophores of P-gp inhibitors of digoxin transport and vinblastine binding suggest some commonality in their binding sites. Utilization of such models may prove to be of value for prediction of molecules that may modulate one or more P-gp binding sites.

Knowledge Graph

Similar Paper

Three-Dimensional Quantitative Structure-Activity Relationships of Inhibitors of P-Glycoprotein
Molecular Pharmacology 2002.0
Functional assay and structure–activity relationships of new third-generation P-glycoprotein inhibitors
Bioorganic & Medicinal Chemistry 2008.0
Ligand-based modeling of diverse aryalkylamines yields new potent P-glycoprotein inhibitors
European Journal of Medicinal Chemistry 2016.0
A Pharmacophore Hypothesis for P-Glycoprotein Substrate Recognition Using GRIND-Based 3D-QSAR
Journal of Medicinal Chemistry 2005.0
Three-Dimensional Quantitative Structure−Activity Relationship Analysis of a Set ofPlasmodium falciparumDihydrofolate Reductase Inhibitors Using a Pharmacophore Generation Approach
Journal of Medicinal Chemistry 2004.0
Pharmacophore Model of Drugs Involved in P-Glycoprotein Multidrug Resistance:  Explanation of Structural Variety (Hypothesis)
Journal of Medicinal Chemistry 2002.0
Three-Dimensional Quantitative Structure-Activity Relationship Analysis of Human CYP51 Inhibitors
Drug Metabolism and Disposition 2007.0
A Novel Approach for Predicting P-Glycoprotein (ABCB1) Inhibition Using Molecular Interaction Fields
Journal of Medicinal Chemistry 2011.0
Pharmacophore Modeling, Quantitative Structure–Activity Relationship Analysis, and in Silico Screening Reveal Potent Glycogen Synthase Kinase-3β Inhibitory Activities for Cimetidine, Hydroxychloroquine, and Gemifloxacin
Journal of Medicinal Chemistry 2008.0
Synthesis, Activity, and Pharmacophore Development for Isatin-β-thiosemicarbazones with Selective Activity toward Multidrug-Resistant Cells
Journal of Medicinal Chemistry 2009.0